TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06106048

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Closed kinetic chain exercises
Description: Group A was treated with closed kinetic chain exercises. Group A: Group A was treated with closed kinetic chain exercises. Closed kinetic chain exercises enhance the proprioception by coordinating the mechanical receptors as well as the strength of the external shoulder rotator muscles, reduce the pain and improve the shoulder.~Closed kinetic chain exercises include:~* Push up~* Scapular push up~* Scapular dip~* Crab walk~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280, wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal contraction exercises
Description: Group B was treated with abdominal contraction exercises for periscapular activation that includes: Wall slide, knee pushup, external rotation kneeling, Full can and External rotation with elevation and isometric low row.~Common Treatment:~Cryotherapy 10 minutes 2 times per day. Ultrasonography 1Mhz frequency, 0.4 watt/cm for 10 minutes. Transcutaneous electrical stimulation (TENS) 10 minutes, modulation mode, frequency 280,wavelength 80.~Cross arm stretching 5 times 30 sec hold. Shoulder isometric exercises 10 repetitions 3 sets for 3 times per week.
Study: NCT06465329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Intravenous (IV) infusion administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cemiplimab
Description: Intravenous (IV) infusion administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Platinum-based chemotherapy
Description: IV infusion

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-based chemotherapy
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN7075
Description: IV infusion
Study: NCT05488639

Intervention type: OTHER
Intervention: Registration of football exposure and occurrence of injuries and illnesses only
Description: Injury \& illness registration~Data on injury and illness is gathered following the recommended methodology in the football extension of the International Olympic Committee consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport. This includes characteristics such as mode of onset, injury mechanism, diagnosis and classification according to body area, tissue, and pathology type, and illness categories for organ system and etiology. Time-loss will be counted in number of days.

Intervention type: OTHER
Intervention: Registration of football exposure and occurrence of injuries and illnesses only
Description: Injury \& illness registration~Data on injury and illness is gathered following the recommended methodology in the football extension of the International Olympic Committee consensus statement on methods for recording and reporting of epidemiological data on injury and illness in sport. This includes characteristics such as mode of onset, injury mechanism, diagnosis and classification according to body area, tissue, and pathology type, and illness categories for organ system and etiology. Time-loss will be counted in number of days.
Study: NCT04909593

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spinal Cord Stimulation
Description: Spinal cord stimulation at varied electrode, pulse width, frequency and amplitude parameters
Study: NCT05672862

Intervention type: DEVICE
Intervention: Percutaneous coronary intervention
Description: PCI was performed using drug-eluting stents
Study: NCT04113226

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with classical Rituximab-based chemotherapy or Rituximab plus Lenalidomide.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide 20 MG
Description: patients ≥ 75 years old with relapsed Diffuse large B-cell lymphoma will be treated with Rituximab plus Lenalidomide. Four 28-days cycles of oral Lenalidomide (20 mg / d for 21 days) and Rituximab 375mg/m2 on day 1 and day 21. After this induction phase, patients achieving at least stable disease were given lenalidomide maintenance therapy (20 mg for 21 days) until progression

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Comprehensive Geriatric Assessment (CGA)
Description: A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,...) on which treatment may impact.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive Geriatric Assessment (CGA)
Description: A comprehensive geriatric assessment (CGA) is recommended by the Société Internationale d'Onco Gériatrie (SIOG) in order to assess all geriatric facets (comorbidity, functional impairment, nutritional status, mental and psychological status, environment,...) on which treatment may impact.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Activities of daily living (ADL) scale
Description: Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Activities of daily living (ADL) scale
Description: Activities of daily living (ADL) comprise the basic actions that involve caring for one's self and body, including personal care, mobility, and eating. The Index ranks adequacy of performance in the six functions of bathing, dressing, toileting, transferring, continence, and feeding. Clients are scored yes/no for independence in each of the six functions. A score of 6 indicates full function, 4 indicates moderate impairment, and 2 or less indicates severe functional impairment.
Study: NCT05483478

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: mobile health combined Multi-course Program
Description: mobile health combined Multi-course Program

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: mobile health combined Multi-course Program
Description: mobile health combined Multi-course Program
Study: NCT05844982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Faricimab
Description: 6.0 mg intravitreal injection at randomization and every 3 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluocinolone acetonide
Description: 0.19 mg fluocinolone acetonide intravitreal implant (Iluvien) at randomization and at 24 months
Study: NCT05424952

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conversational AI Service (Chatbot)
Description: WhatsApp or Messenger Chatbot for COVID-19 vaccines
Study: NCT05727878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPI-012
Description: KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPI-012
Description: KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KPI-012
Description: KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: KPI-012 Vehicle
Description: KPI-012 formulation with no active drug
Study: NCT05363839

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-000029
Description: ACH-000029 will be administered orally via a capsule.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally via a capsule.
Study: NCT04867551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KDT-3594
Description: oral administration, dose titration
Study: NCT05048316

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Stress Management and Health Education
Description: Participants will attend group sessions with a trained facilitator held over videoconference. Sessions will each last 2 hours and will be held once weekly for 10 weeks. Sessions will include Cognitive-Behavioral Stress Management and health education content.
Study: NCT04830579

Intervention type: DRUG
Group type: OTHER
Intervention: Etoricoxib film-coated tablet 120 mg
Description: Etoricoxib is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 120 mg of etoricoxib.

Intervention type: DRUG
Group type: OTHER
Intervention: Etoricoxib film-coated tablet 120 mg
Description: Etoricoxib is manufactured by Pharmtechnology LLC, Republic of Belarus. Each tablet contains 120 mg of etoricoxib.

Intervention type: DRUG
Group type: OTHER
Intervention: Arcoxia® film-coated tablet 120 mg
Description: Arcoxia® is manufactured by Frosst Iberica SA, Spain. Each tablet contains 120 mg of etoricoxib.

Intervention type: DRUG
Group type: OTHER
Intervention: Arcoxia® film-coated tablet 120 mg
Description: Arcoxia® is manufactured by Frosst Iberica SA, Spain. Each tablet contains 120 mg of etoricoxib.
Study: NCT04472949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab: 1500 mg iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Carboplatin: AUC 5 mg/mL/min iv

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Etoposide: 100 mg/m2 iv

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Thoracic radiotherapy
Description: Thoracic radiotherapy: 39 Gy in 13 fractions, starting 3-8 weeks after day 1 of last cycle of induction treatment, over 2.5 weeks Prophylactic cranial irradiation (PCI) is allowed but optional: according to local practice, starting 3-8 weeks after day 1 of last cycle of induction treatment Follow up phase Patients will be followed up for 24 months, every 8 weeks.
Study: NCT06513169

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Group 1: LEE
Description: Patients will be in supine position during induction with a 12 wedge placed at the level of the Achilles tendon (LEE)
Study: NCT06465433

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafasitamab
Description: Treatment with tafasitamab is as per the treatment dose and schedule they received in the parent protocols.
Study: NCT05185726

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lidcombe Program
Description: The LP consists of Stage 1 and Stage 2. Stage 1 aims at reducing the stuttering of the PCWS to (near) zero levels of stuttering. During stage 1, parents learn to provide verbal contingencies during daily, 10-minute practice sessions with their PCWS.~During Stage 1, treatment sessions are scheduled weekly. When the child has typical scores of 0 and 1 on the SR-scale with more 0s than 1s per week for three consecutive weeks, and the stuttering is rated as 0 or 1 during the treatment session, the child can proceed to stage 2.~The maintenance phase starts when the stuttering is reduced to (near) zero stuttering and parents are able to implement the practice sessions when it is necessary (when stuttering relapses). Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mini-KIDS
Description: Mini-KIDS for 4-6-year old PCWS consists of four stages: Stage 1 = desensitization, Stage 2 = identification, Stage 3 = modification and Stage 4 = generalization. The program for 2-4-year old child does not include stage 2. SLT and parent(s) are the speech model for the child. They add normal disfluencies and pseudo-stuttering to their speech at first to make sure the child dares to stutter and the child as well as the parent(s) are desensitized for it. Later on in treatment and if necessary, child learn to recognise and alter their stuttering moments. The maintenance phase starts when the child and parent(s) achieved the goals of Stage 4. Usually the stuttering is reduced to (near) zero stuttering. Treatment sessions to monitor if achieved goals are maintained are scheduled with an interval of 2, 2, 4, 4, 8, 8 and 16 weeks.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognitive Behavioural Therapy
Description: A parent training is organised for parents with children who stutters who receive SCBT.~The parent training exists of 10 one-hour group evening sessions for parents to discuss and offer education topics about what stuttering is, how stuttering looks like, ...~The program is delivered in 5 phases and each phase takes as long as is necessary for the PCWS (variable): (1) conditioning speaking activities, (2) cognitive training focused on emotions, (3) cognitive training focused on cognitions, (4) emotional training and (5) skill training.~The maintenance phase starts when the child and parent(s) achieved the goals of the 5 phases. During the maintenance sessions, the SLT asks the parent(s) to report about the child and observes the speech of the child.
Study: NCT05551858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proglumide
Description: (CAS: 6620-60-6.)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Avicel fiber filled capsule taken by mouth three times daily
Study: NCT05019872

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: (Components of) pasta meal
Description: Samples will be provided one by one in cups labeled with an unique code.
Study: NCT04827446

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wearable Sensor
Description: Patient is given a wearable device to wear for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wearable Sensor
Description: Patient is given a wearable device to wear for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blue-blocking glasses
Description: Patient is given blue-blocking glasses to wear at instructed times.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Clear glasses
Description: Patient is given glasses that block no visible light.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Full SYNC app
Description: Patient downloads the SYNC app and is given light interventions designed to have a targeted, personalized effect on the circadian clock.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dummy SYNC app
Description: Patient downloads the SYNC app and is given light interventions designed to have minimal impact on the circadian clock.
Study: NCT04931875

Intervention type: DEVICE
Intervention: Total body PET/CT (uExplorer)
Description: A total-body PET/CT scanner (uEXPLORER) with a 194-cm scan range will be applied in patients affected with lymphoma.
Study: NCT04862247

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imaginal Exposure Condition
Description: Participants will be asked to think and write about an eating related fear or anxiety. Specifically, they will be asked to spend 20-30 minutes writing about a specific fear or anxiety they have, then another 20-35 minutes re-reading and imagining that what they have written is happening.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Writing and Thinking Condition
Description: Participants will be asked to think and write about their eating disorder using specific prompts designed to help them process their eating disorder. Specifically, they will be asked to spend 20-30 minutes writing their eating disorder, then another 20-35 minutes re-reading what they wrote.
Study: NCT05178199

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: RPSG
Description: The RPSG program include sharing successful experience, progressive muscle relaxation (PMR), and mindfulness-based stress reduction (MBSR). The duration is at last 8 weeks and includes 1 hour per week of RPSG activities.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: RPSG
Description: The RPSG program include sharing successful experience, progressive muscle relaxation (PMR), and mindfulness-based stress reduction (MBSR). The duration is at last 8 weeks and includes 1 hour per week of RPSG activities.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: AVMBM
Description: The duration is also at last 8 weeks and includes encouraging to use 5 minutes Audio and Video Mindfulness of Breathing Meditation (AVMBM) per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: AVMBM
Description: The duration is also at last 8 weeks and includes encouraging to use 5 minutes Audio and Video Mindfulness of Breathing Meditation (AVMBM) per week.
Study: NCT05874284

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gelofusin
Description: In the experimental group, the wound will be washed with gelofusine as prolotherapy, and the wound will be closed with sterile sponge and fixative tape. In the control group, the wound will be covered with sterile sponge and fixative tape by washing with physiological saline.
Study: NCT06307418

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carer eSupport
Description: Internet-based support
Study: NCT06008392

Intervention type: GENETIC
Intervention: Pan-genomic Testing
Description: Participants will be scheduled to review the study specifics, review consent and gather medical information. Once consented, samples will be collected. When the samples are received by Exact Sciences, DNA and RNA will be extracted, and sequencing will be performed. Following pan-genomic testing, participants will receive the full report with results from their care team and results will also be added to the patient's portal. If a germline finding is identified (positive pathogenic variant) the participant will also be referred for a genetic counselor visit. All results from the germline hereditary test will be reviewed by a certified genetic counselor in addition to a review of their pedigree. To help with review of any genetic research findings, the study team may request to obtain genomic data from previous genetic testing (clinical or research based).
Study: NCT05392309

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual ankle rocking training
Description: Group will receive manual ankle rocking training with lower limb exercise and core strengthening of trunk

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Conventional
Description: Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional
Description: Group will receive lower limb exercises and core strengthening of trunk. Sessions will be 4 days in a week
Study: NCT06137976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastric decompression (oropharyngeal or nasopharyngeal gastric tube)
Description: Placement of tube through the nose or mouth into the stomach for gastric decompression
Study: NCT04653285

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: motor skill practice
Description: Motor learning task on a stability platform (stabilometer). Participants try to keep the tiltable platform in a horizontal position in trials of 30s.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: motor skill practice
Description: Motor learning task on a stability platform (stabilometer). Participants try to keep the tiltable platform in a horizontal position in trials of 30s.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: A bout of moderate intensity aerobic exercise on a cycle ergometer following motor skill practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rest
Description: Seated rest following motor skill practice.
Study: NCT06015061

Intervention type: DIAGNOSTIC_TEST
Intervention: Contrast-enhanced ultrasound(CEUS)
Description: CEUS is a quantitative kinetic imaging modality that can assess intravascular blood flow in PPGL tumors.
Study: NCT06396819

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: collagen-povidone solution
Description: Application of collagen-povidone solution at a dose of 0.2 cc, compared with the application of physiological solution in the control group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: collagen-povidone solution
Description: Application of collagen-povidone solution at a dose of 0.2 cc, compared with the application of physiological solution in the control group
Study: NCT06048484

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimberelimab
Description: 240 mg intravenously (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Quemliclustat
Description: 100 mg IV
Study: NCT04883866

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telephone Breastfeeding Support Program
Description: On the 3rd day after discharge, a reminder messages will be sent to the mothers in the inter vention group. Throughout the program, 21 reminder messages will be sent to mothers in the first month after discharge to support the mother and encourage breast milk via a messaging application (whatsapp, bip, telegram, etc.). In addition, a total of seven phone calls, once a week in the first month after discharge and once a month in the eighth, twelfth and sixteenth weeks, will be made to check personalized information about individual breastfeeding questions of mothers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sending a breastfeeding guide for premature babies to the phone of mothers in addition to the routine discharge procedure
Description: In addition to the routine discharge procedure, a breastfeeding guide for premature babies will be sent to the mothers' phone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sending a breastfeeding guide for premature babies to the phone of mothers in addition to the routine discharge procedure
Description: In addition to the routine discharge procedure, a breastfeeding guide for premature babies will be sent to the mothers' phone.